Drug Shortage Report for HYDROMORPHONE HYDROCHLORIDE INJECTION, USP

Last updated on 2024-09-20 History
Report ID 201627
Drug Identification Number 02491680
Brand name HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
Common or Proper name HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) HYDROMORPHONE HYDROCHLORIDE
Strength(s) 10MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging sizes (GTIN)

Click here to see a list of all reports for this drug.

(See additional packaging sizes)
Additional packaging sizes 5 mL
ATC code N02AA
ATC description OPIOIDS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2023-10-01
Actual start date
Estimated end date Unknown
Actual end date 2024-09-19
Shortage status Resolved
Updated date 2024-09-20
Company comments Fresenius Kabi Canada regrets to advise that due to production delays, we are facing a supply interruption on our HYDROmorphone Hydrochloride Injection, USP 10 mg/mL SD Vial 5 mL.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v17 2024-09-20 English Compare
v16 2024-09-19 French Compare
v15 2024-09-19 English Compare
v14 2024-07-11 French Compare
v13 2024-07-11 English Compare
v12 2024-07-02 French Compare
v11 2024-07-02 English Compare
v10 2024-07-02 English Compare
v9 2024-04-05 French Compare
v8 2024-04-05 English Compare
v7 2024-01-09 French Compare
v6 2024-01-09 English Compare
v5 2023-11-01 French Compare
v4 2023-11-01 English Compare
v3 2023-10-02 English Compare
v2 2023-08-11 French Compare
v1 2023-08-11 English Compare

Showing 1 to 17 of 17